Premium
IFI16 reduced expression is correlated with unfavorable outcome in chronic lymphocytic leukemia
Author(s) -
Piccaluga Pier Paolo,
Agostinelli Claudio,
Righi Simona,
Ciccone Maria,
Re Maria Carla,
Musumeci Giuseppina,
Diani Erica,
Signoretto Caterina,
Bon Isabella,
Piccin Ottavio,
Cuneo Antonio,
Tripodo Claudio,
Ponti Cristina,
Zipeto Donato,
Landolfo Santo,
Gibellini Davide
Publication year - 2017
Publication title -
apmis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 88
eISSN - 1600-0463
pISSN - 0903-4641
DOI - 10.1111/apm.12692
Subject(s) - chronic lymphocytic leukemia , immunohistochemistry , phenotype , flow cytometry , leukemia , gene expression profiling , variable expression , biology , immunology , cancer research , gene , gene expression , medicine , oncology , pathology , genetics
Chronic lymphocytic leukemia ( CLL ) is the most common leukemia in adults. Its clinical course is typically indolent; however, based on a series of pathobiological, clinical, genetic, and phenotypic parameters, patient survival varies from less than 5 to more than 20 years. In this paper, we show for the first time that the expression of the interferon‐inducible DNA sensor IFI 16, a member of the PYHIN protein family involved in proliferation inhibition and apoptosis regulation, is associated with the clinical outcome in CLL . We studied 99 CLL s cases by immunohistochemistry and 10 CLL s cases by gene expression profiling. We found quite variable degrees of IFI 16 expression among CLL s cases. Noteworthy, we observed that a reduced IFI 16 expression was associated with a very poor survival, but only in cases with ZAP 70/ CD 38 expression. Furthermore, we found that IFI 16 expression was associated with a specific gene expression signature. As IFI 16 can be easily detected by immunohistochemistry or flow cytometry, it may become a part of phenotypic screening in CLL patients if its prognostic role is confirmed in independent series.